13 results about "Cardioversion" patented technology

The invention involves a novel method of converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL by administering at least a loading dose of dofetilide intravenously, or if that fails cardioversion and a maintenance infusion followed by a switch to chronic oral dosing.

The present invention provides a pharmacological wearable cardioverter defibrillation system for conducting cough assisted pharmacological cardioverter defibrillation during onset of a sudden arrhythmia. The system comprises a WCD defibrillator worn by the patient, a drug mix contained either in a reservoir / pump or in an inhaler, and a miniature monitor. The drug mix in the reservoir / pump is equipped with a pump for pumping the drug mix via an indwelling catheter to the coronary sinus while the drug mix in the inhaler is inhaled directly to the lungs. When a sudden arrhythmia is detected by a sensing electrode of WCD, the following steps are carried out: prompting the patient to take the drug mix, prompting the patient to start forceful coughing, and delivering electric shock(s) under either one of the two circumstances that the patient is unable to start coughing or the arrhythmia is not terminated.

The invention discloses a construction method and application of a spontaneous atrial fibrillation mouse model, and belongs to the technical field of atrial fibrillation animal models. According to the construction method, a whole-body DYNLT1 gene knockout mouse is constructed by using technologies such as gene editing and the like, the DYNLT1 gene knockout mouse is systematically evaluated through methods such as body surface electrocardiogram, echocardiography and histopathologic examination, and the DYNLT1 gene knockout mouse shows typical characteristics of atrial fibrillation in the aspects of body surface electrophysiology, atrial structure remodeling and the like. And in the molecular level, atrial muscle cell apoptosis is increased, gap junction protein expression is reduced, and inflammatory factor level is increased, so that the model is confirmed to be a spontaneous atrial fibrillation mouse model. In addition, the model shows a rapid drug reaction to the atrial fibrillation cardioversion drugs, such as amiodarone and propafenone, and has the potential for screening the atrial fibrillation drugs. The animal model provides a new pathological model for atrial fibrillation mechanism research and drug screening, and has important scientific research and clinical application values.

The utility model discloses an improved tile type action cardioversion auxiliary device which comprises a bite handle and a fixing cylinder arranged on the rear side of the bite handle, a conveying sleeve is connected to the rear side of the fixing cylinder, a conveying cylinder is connected to the rear side of the conveying sleeve, a connecting pipe is connected to the rear side of the conveying cylinder, and the connecting pipe is connected to the rear side of the fixing cylinder. A monitoring balloon is connected to the exterior of the rear side of the connecting pipe, an adjusting cylinder is arranged on the outer side of the conveying cylinder, and the blowing condition of the patient can be visually displayed through the monitoring balloon. A doctor and a patient can accurately judge the blowing strength and effect by observing the expansion degree of the monitoring balloon, so that the blowing strength is adjusted in time, the accuracy of the cardioversion operation is ensured, and the airflow strength can be accurately adjusted according to the requirements and actual conditions of different patients through matched use of the adjusting cylinder and the adjusting ball. The personalized adjusting function is beneficial to improving the success rate of the cardioversion, so that the treatment is more accurate.

An automated resuscitation system is provided, which can improve the outcome of patients suffering ventricular fibrillation or the ventricular tachycardia variants of cardiac arrest. This outcome can be achieved by a device that integrates automatic mechanical or pneumatic capability with electrical countershock capability such that the probability of defibrillation or cardioversion with return of spontaneous circulation is increased.

The invention discloses an implantable cardioversion defibrillation system, a medical event prediction method and a medium. The system comprises: a signal acquisition assembly configured to acquire a multi-modal physiological signal; the processor comprises a feature extraction module configured to extract key features from the multi-modal physiological signals to obtain a key feature sequence; the hemodynamics stability model prediction module is configured to process the key feature sequence of the physiological signal to obtain a feature vector sequence; splicing the feature vector sequence of each mode to form a multi-mode comprehensive feature tensor; determining a cross-modal association feature vector based on the association relationship of the multi-modal comprehensive feature tensor; performing feature splicing on the feature vector sequence and the cross-modal association feature vector to generate a fusion feature matrix; based on the fused feature matrix, a haemodynamic instability indicator is predicted. According to the embodiment of the invention, the function of the implantable cardioverter defibrillation system can be enriched.

Disclosed are methods for cardioversion using bundanolol or a pharmaceutical composition comprising bundanolol for cardioversion of patients with paroxysmal or persistent AFib.

Disclosed are cardioversion methods for patients with either paroxysmal or persistent AFib which methods use budiodarone or a pharmaceutical composition comprising budiodarone.

Disclosed herein are methods and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using potassium channel inhibitors and class I antiarrhythmic agents. Also disclosed herein are methods and kits for treating a heart condition via an intravenously, orally, or inhalationally administered fixed-dose combination of a sodium channel blocker and a class I antiarrhythmic agent.

The invention disclosed here relates in general to the field of medical devices. In particular, to devices and methods for improving the clinical outcome of patients suffering from cardiac dysrhythmias without cardiac arrest. This method and / or device integrates mechanical, pneumatic, acoustic and / or electrophysiologic capabilities with electrical countershock or pacing capabilities such that the probability of successful cardioversion or pacing is increased. The sequence, forces, and electrical properties of the subsystems can be computer controlled and adjusted in response to biomarker inputs.

Electrical medical therapy systems, devices, and methods can employ “electrodes” that are galvanically isolated from target biologic tissue. An electric field can be generated in the biologic tissue via such electrically insulated and galvanically isolated electrodes. Further the electric field can be directionally varied, such as to form a Rotating Electric Field (REF), such that it can impact biological cells from different directions. Directional variation of the electric field can be obtain using a set of three (triad) or more electrodes, or multiple such sets or triads, and applying respective phase-delayed time-varying electric signals to corresponding individual electrodes in the triad or other set of galvanically isolated electrodes. Medical electrical REF therapies can include, among other things, at least one of cardioversion, defibrillation, pacing or other cardiac resynchronization, ablation, cautery, vessel sealing, or thermal sterilization.

The invention disclosed here relates in general to the field of medical devices. In particular, to devices and methods for improving the clinical outcome of patients suffering from cardiac dysrhythmias without cardiac arrest. This method and / or device integrates mechanical, pneumatic, acoustic and / or electrophysiologic capabilities with electrical countershock or pacing capabilities such that the probability of successful cardioversion or pacing is increased. The sequence, forces, and electrical properties of the subsystems can be computer controlled and adjusted in response to biomarker inputs.

The present invention relates to a safe dosage regimen comprising administering a dose of dofelilide IV followed by oral administration of dofelilide. In a first aspect, the present invention relates to a method of reducing the risk of atrial fibrillation (AF) and / or atrial flutter (AFL) following coronary artery bypass surgery (CABS) by intravenously administering a loaded dose and a sustaining dose of dofililide followed by an oral dose. In a second aspect, the present invention relates to a method of terminating an arrhythmic storm in a patient after implementation of an implantable defibrillator by loading and maintaining infusion and then oral administration of doferide intravenously. In a third aspect, the present invention also relates to a method of transforming atrial fibrillation (AF) or atrial flutter (AFL) in a patient suffering from highly symptomatic AF or AFL by intravenous administration of at least a loading dose of dofililide, or if it fails, cardioversion and maintenance of infusion, followed by long term oral administration.